Summarized by Masters of Longevity from Longevity Technology.
An article previewing early human trial results of an experimental oral drug targeting a key inflammatory protein, and what the findings could mean for cardiovascular and age-related inflammation.
Key Takeaways
- An oral molecular glue degrader, MRT-8102, reduced NEK7 protein levels by a median of roughly 80–90% in treated participants.
- Treatment with MRT-8102 produced substantial median reductions in multiple cardiovascular inflammation biomarkers, including hsCRP (85%), IL-6 (54%), and plaque-linked proteins S100A12, calprotectin, and SAA (46–56%).
- Phase 2 studies to evaluate clinical effects and long-term safety in coronary artery disease and other inflammatory conditions are planned to start in 2026–2027.
